<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The value of implantable cardioverter defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) in adults with <z:hpo ids='HP_0002564'>congenital heart disease</z:hpo> (CHD) is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the long-term outcome after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation and developed a simple risk stratification score for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: A total of 136 adults with CHD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> (mean age±SD, 41±13 years; 67% male) were identified from 10 tertiary referral centers in the Netherlands and Belgium </plain></SENT>
<SENT sid="3" pm="."><plain>The indication for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation was primary prevention in 50% of patients </plain></SENT>
<SENT sid="4" pm="."><plain>Diagnoses included <z:hpo ids='HP_0001636'>tetralogy of Fallot</z:hpo> (51%), <z:hpo ids='HP_0001671'>septal defects</z:hpo> (20%), (congenitally corrected) <z:hpo ids='HP_0001669'>transposition of the great arteries</z:hpo> (13%), and other (16%) </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-nine patients (29%) received appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks during a median follow-up of 4.6 years </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary prevention indication (hazard ratio [HR], 3.6; 95% CI, 1.3-9.5; P=0.009), <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (HR, 2.7; 95% CI, 1.0-7.2; P=0.042), and symptomatic nonsustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (NSVT; HR, 9.1; 95% CI, 2.8-29.2; P=0.001) were associated with appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks </plain></SENT>
<SENT sid="7" pm="."><plain>A risk score was developed to evaluate the likelihood of appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks </plain></SENT>
<SENT sid="8" pm="."><plain>The 8-year survival curve to first appropriate shocks was 94%, 57%, and 26% for low-, intermediate-, and high-risk patients, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>In primary prevention, symptomatic NSVTs (HR, 8.0; 95% CI, 2.3-27.1; P=0.001) and subpulmonary ventricular dysfunction (HR, 3.0; 95% CI, 1.2-12.6; P=0.02) were associated with appropriate shocks in univariable analysis </plain></SENT>
<SENT sid="10" pm="."><plain>Inappropriate shocks occurred in 41 patients (30%) </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, 40 patients (29%) experienced 45 implantation-related complications </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Adults with CHD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> receive high rates of appropriate and effective shocks </plain></SENT>
<SENT sid="13" pm="."><plain>Patients with secondary prevention indication, <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, and symptomatic NSVT are at highest risk of receiving appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks </plain></SENT>
<SENT sid="14" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation is accompanied by considerable morbidity, including inappropriate shocks and procedure- related complications </plain></SENT>
</text></document>